Concordant Analysis of KRAS, BRAF, PIK3CA Mutations, and PTEN Expression Between Primary Colorectal Cancer and Matched Metastases

Overview

Journal Sci Rep

Specialty Science

Date 2015 Feb 3

PMID 25639985

Citations 61

Authors

Chen Mao

Xin-Yin Wu

Zu-Yao Yang

Diane Erin Threapleton

Jin-Qiu Yuan

Yuan-Yuan Yu

Jin-Ling Tang

Affiliations

Soon will be listed here.

Abstract

Current data on the concordance of KRAS, BRAF, PIK3CA mutation status or PTEN expression status between primary tumors and metastases in colorectal cancer (CRC) are conflicting. We conducted a systematic review and meta-analysis to examine concordance and discordance of the status of these four biomarkers between primary tumors and corresponding metastases in CRC patients. The biomarker status in primary tumors was used as the reference standard. Concordance data for KRAS, BRAF, PIK3CA and PTEN were provided by 43, 16, 9 and 7 studies, respectively. The pooled concordance rate was 92.0% (95% CI: 89.7%-93.9%) for KRAS, 96.8% (95% CI: 94.8%-98.0%) for BRAF, 93.9% (95% CI: 89.7%-96.5%) for PIK3CA and 71.7% (95% CI: 57.6%-82.5%) for PTEN. The pooled false positive and false negative rates for KRAS were 9.0% (95% CI: 6.5%-12.4%) and 11.3% (95% CI: 8.0%-15.8%), respectively. KRAS, BRAF and PIK3CA mutations are highly concordant between primary tumors and corresponding metastases in CRC, but PTEN loss is not. Nine percent of patients with wild-type KRAS in primary tumors who received anti-EGFR treatment had mutant KRAS in metastases, while 11.3% patients with mutant KRAS primary tumors had wild-type KRAS in the metastases. These 11.3% patients currently do not receive potentially beneficial anti-EGFR treatment.

Citing Articles

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives.

Takeda M, Yoshida S, Inoue T, Sekido Y, Hata T, Hamabe A Cancers (Basel). 2025; 17(3).

PMID: 39941797 PMC: 11816235. DOI: 10.3390/cancers17030428.

The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies.

Wang H, Tang R, Jiang L, Jia Y Front Pharmacol. 2024; 15:1494802.

PMID: 39555098 PMC: 11565213. DOI: 10.3389/fphar.2024.1494802.

Prognostic role of immunohistochemical PTEN (phosphatase and tensin homolog) expression and PTEN (rs701848) genotypes among Egyptian patients with different stages of colorectal cancer.

Osman H, Hassan M, Toema A, Abdelnaby A, Abozeid M, Mohamed M J Cancer. 2024; 15(15):5046-5057.

PMID: 39132163 PMC: 11310872. DOI: 10.7150/jca.97553.

Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.

Popescu I, Croitoru V, Croitoru-Cazacu I, Dudau A, Herlea V, Dima S J Pers Med. 2024; 14(7).

PMID: 39064004 PMC: 11278408. DOI: 10.3390/jpm14070750.

Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.

Ciepiela I, Szczepaniak M, Ciepiela P, Hincza-Nowak K, Kopczynski J, Macek P Sci Rep. 2024; 14(1):4619.

PMID: 38409377 PMC: 10897470. DOI: 10.1038/s41598-024-55139-w.

References

Oudejans J, Slebos R, Zoetmulder F, Mooi W, Rodenhuis S . Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer. 1991; 49(6):875-9. DOI: 10.1002/ijc.2910490613. View

Zauber P, Sabbath-Solitare M, Marotta S, Bishop D . Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003; 56(3):137-40. PMC: 1187308. DOI: 10.1136/mp.56.3.137. View

Losi L, Benhattar J, Costa J . Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer. 1992; 28A(6-7):1115-20. DOI: 10.1016/0959-8049(92)90468-h. View

Paliogiannis P, Cossu A, Tanda F, Palmieri G, Palomba G . mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett. 2014; 8(4):1422-1426. PMC: 4156255. DOI: 10.3892/ol.2014.2411. View

Bardelli A, Siena S . Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010; 28(7):1254-61. DOI: 10.1200/JCO.2009.24.6116. View

Suchy B, Zietz C, Rabes H . K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer. 1992; 52(1):30-3. DOI: 10.1002/ijc.2910520107. View

Thebo J, Senagore A, Reinhold D, Stapleton S . Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Colon Rectum. 2000; 43(2):155-9; discussion 159-62. DOI: 10.1007/BF02236973. View

Garm Spindler K, Pallisgaard N, Rasmussen A, Lindebjerg J, Andersen R, Cruger D . The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol. 2009; 20(5):879-84. DOI: 10.1093/annonc/mdn712. View

Baldus S, Schaefer K, Engers R, Hartleb D, Stoecklein N, Gabbert H . Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010; 16(3):790-9. DOI: 10.1158/1078-0432.CCR-09-2446. View

10.

Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E . KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2006; 26(1):158-63. DOI: 10.1038/sj.onc.1209758. View

11.

Schimanski C, Linnemann U, Berger M . Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res. 1999; 59(20):5169-75. View

12.

Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M . PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2008; 20(1):84-90. DOI: 10.1093/annonc/mdn541. View

13.

Mostert B, Jiang Y, Sieuwerts A, Wang H, Vries J, Biermann K . KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2012; 133(1):130-41. DOI: 10.1002/ijc.27987. View

14.

Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E . High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008; 13(12):1270-5. DOI: 10.1634/theoncologist.2008-0181. View

15.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

16.

Kaneko Y, Kuramochi H, Nakajima G, Inoue Y, Yamamoto M . Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. Int J Clin Oncol. 2013; 19(1):113-20. DOI: 10.1007/s10147-012-0507-4. View

17.

Cejas P, Lopez-Gomez M, Aguayo C, Madero R, Moreno-Rubio J, De Castro Carpeno J . Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. Curr Cancer Drug Targets. 2012; 12(2):124-31. DOI: 10.2174/156800912799095162. View

18.

Finkelstein S, Sayegh R, Christensen S, Swalsky P . Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer. 1993; 71(12):3827-38. DOI: 10.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-n. View

19.

Knijn N, Mekenkamp L, Klomp M, Vink-Borger M, Tol J, Teerenstra S . KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011; 104(6):1020-6. PMC: 3065268. DOI: 10.1038/bjc.2011.26. View

20.

Baas J, Krens L, Guchelaar H, Morreau H, Gelderblom H . Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011; 16(9):1239-49. PMC: 3228174. DOI: 10.1634/theoncologist.2011-0024. View